---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-26-000056"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2026-05-21T20:13:01+00:00"
generated_at: "2026-05-21T20:14:40.502320+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma stockholders approve Amended 2022 Stock Plan, elect seven directors

## Summary
- Approved Amended 2022 Stock Plan; authorized share reserve increased by 962,000 to 8,222,000 shares.
- All seven director nominees elected: Haughey, Lalwani, Leonard, Pera, Shanmugam, Tannenbaum, Thoma.
- Ratified Ernst & Young as independent auditor for fiscal year 2026.
- Advisory say-on-pay vote approved; future votes to be held every one year.
- Amended plan includes no-hedging policy on repricing and director compensation cap of $750k per year.

## SEC filing metadata
- accession: 0001023024-26-000056
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2026-05-21T20:13:01+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000056/0001023024-26-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000056/ani-20260521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-26-000056
- JSON: https://secwatch.observer/filing/0001023024-26-000056.json
- Plain text: https://secwatch.observer/filing/0001023024-26-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.